Navigation Links
Labopharm's Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
Date:7/31/2008

- Product Now Being Sold in 14 Countries Worldwide -

LAVAL, QC, July 31 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that its once-daily formulation of tramadol has been launched in the following countries:

South Korea - Labopharm's marketing partner for South Korea, WhanIn Pharmaceutical Co. Ltd., launched the product in July under the brand name TramaConti CR(R).

Australia - Labopharm's marketing partner for Australia, iNova Pharmaceuticals (Australia) Pty Limited launched the product in July under the brand name Durotram XR(R).

Romania - Labopharm's marketing partner for Romania, CSC Pharmaceuticals, launched the product in July under the brand name Noax(R) Uno.

Austria - Labopharm's marketing partner for Austria, CSC Pharmaceuticals, launched the product in June under the brand name Noax(R) Uno.

"With these launches, our once-daily tramadol product is now being sold in 14 countries that, combined, account for almost 55% of the world's market for tramadol products," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "South Korea and Australia, in particular, represent significant opportunities as the 6th and 12th largest markets for tramadol products in the world, respectively. We look forward to leveraging the experience we have gained through our previous European and Canadian launches and working with our marketing partners to maximize our product's potential in these markets."

Labopharm's product is available in 100mg, 200mg and 300mg dosage strengths in Australia, Austria and Romania and in 100mg and 200mg dosage strengths in South Korea. The 300 mg dosage strength is approved for sale in South Korea and may be marketed at a later date.

About Labopharm's Once-Daily Tramadol Product

Labopharm's once-daily tramadol product is based on the Company's proprietary Contramid(R) technology, which provides a dual matrix delivery system allowing both rapid and sustained drug release that maintains blood levels within the therapeutic range providing a full 24 hours of pain relief. The Company believes that maintaining drug concentrations within the therapeutic range has the advantage of fewer and less severe side effects while maintaining efficacy. Under its global commercialization program, Labopharm's once-daily tramadol product has been launched in 14 countries, including the five largest markets in Europe and Canada and is approved in 16 other countries. Including those countries in which its product has been launched, Labopharm has licensing and distribution agreements in place for more than 50 markets globally.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New Data Highlights Positive Results of Namenda (Memantine HCl) Once-Daily Extended-Release Formulation
2. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
3. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
4. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
5. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
6. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
7. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
8. Once-Daily Insulin Shot Proves Effective in Study
9. A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status
10. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful for ... , All through the year, Garden Media aims to provide material helpful to ... influencers and pitching client’s key messages to gain coveted media placements, Garden ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions of ... United States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting ... offers strategies for the healthcare community to help decrease the number of completely ...
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards for eating ... of disordered eating, announced today that the 2017 Symposium set a new attendance record ... countries converged on the Green Valley Resort in Las Vegas. , “We are ...
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
(Date:3/24/2017)... Texas (PRWEB) , ... March 24, 2017 , ... ... 2017 the year of enhancements, upgrading their training and leads programs. , In ... University. Reserved for elite sales agents, Performance Partners is designed to teach how ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of the "Deep ... to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 report examines ... deep learning solutions within the healthcare domain. Primarily driven by the ... solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... , March 24, 2017 Global ... industry including definitions, classifications, applications and industry chain structure. ... market including development history, competitive landscape analysis, and major ... ... spread across 105 pages providing 10 company profiles and ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... their offering. ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America , and Rest of ... 2022. Also, a six-year historic analysis is provided for these markets. Market ...
Breaking Medicine Technology: